Guiyang Xintian Pharmaceutical Co Ltd Tangible Net Worth Ratio
Guiyang Xintian Pharmaceutical Co Ltd tangible net worth ratio. Guiyang Xintian Pharmaceutical Co Ltd (002873) has a Tangible Net Worth Ratio of 83.7% as of March 2026. This metric is calculated by deducting intangible assets (CN¥204.73 Million) from net assets (CN¥1.26 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Check 002873 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Guiyang Xintian Pharmaceutical Co Ltd (2012–2025)
Tangible net worth ratio of Guiyang Xintian Pharmaceutical Co Ltd from 2012 to 2025. This chart shows how Guiyang Xintian Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 14 annual periods from 2012 to 2025. As of March 2026, the ratio stands at 83.7%, reflecting net assets of CN¥1.26 Billion with intangible assets of CN¥204.73 Million CNY. See 002873 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Guiyang Xintian Pharmaceutical Co Ltd Tangible Net Worth Ratio by Year (2012–2025)
Guiyang Xintian Pharmaceutical Co Ltd tangible net worth ratio by year from 2012 to 2025. The table below presents the year-by-year Tangible Net Worth Ratio for Guiyang Xintian Pharmaceutical Co Ltd from 2012 to 2025, covering 14 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see 002873 stock market capitalisation.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 84.0% | CN¥1.26 Billion | CN¥201.05 Million | CN¥2.12 Billion | ▲ +0.2 pp |
| 2024 | 83.8% | CN¥1.19 Billion | CN¥194.01 Million | CN¥1.95 Billion | ▼ -1.4 pp |
| 2023 | 85.2% | CN¥1.11 Billion | CN¥165.04 Million | CN¥1.91 Billion | ▼ -1.6 pp |
| 2022 | 86.8% | CN¥1.13 Billion | CN¥149.15 Million | CN¥1.84 Billion | ▲ +2.3 pp |
| 2021 | 84.5% | CN¥890.44 Million | CN¥137.69 Million | CN¥1.52 Billion | ▲ +0.5 pp |
| 2020 | 84.1% | CN¥828.30 Million | CN¥131.94 Million | CN¥1.54 Billion | ▲ +0.7 pp |
| 2019 | 83.4% | CN¥708.76 Million | CN¥117.78 Million | CN¥1.08 Billion | ▼ -3.0 pp |
| 2018 | 86.4% | CN¥660.59 Million | CN¥89.85 Million | CN¥984.31 Million | ▲ +0.9 pp |
| 2017 | 85.5% | CN¥622.11 Million | CN¥89.99 Million | CN¥856.40 Million | ▲ +18.3 pp |
| 2016 | 67.3% | CN¥279.21 Million | CN¥91.38 Million | CN¥549.54 Million | ▲ +8.3 pp |
| 2015 | 59.0% | CN¥226.31 Million | CN¥92.84 Million | CN¥499.36 Million | ▲ +8.4 pp |
| 2014 | 50.6% | CN¥190.50 Million | CN¥94.18 Million | CN¥467.76 Million | ▲ +10.0 pp |
| 2013 | 40.5% | CN¥157.38 Million | CN¥93.59 Million | CN¥379.74 Million | ▼ -10.5 pp |
| 2012 | 51.0% | CN¥178.44 Million | CN¥87.44 Million | CN¥336.84 Million | — |